孕期使用抑酸药与儿童哮喘风险的荟萃分析
该系统综述与荟萃分析检索截至2017年6月的多个数据库,纳入8项观察性人群研究。汇总结果显示,孕期使用抑酸药与儿童期哮喘风险升高相关(RR=1.45,95%CI 1.35-1.56,I2=0%,P<.00001)。质子泵抑制剂使用者的儿童哮喘风险也升高(RR=1.34,95%CI 1.18-1.52),组胺2受体拮抗剂使用者同样升高(RR=1.57,95%CI 1.46-1.69)。
要点
- 孕期使用抑酸药与儿童期哮喘风险升高相关(RR=1.45,95%CI 1.35-1.56)。
- 质子泵抑制剂使用者儿童哮喘风险升高(RR=1.34,95%CI 1.18-1.52)。
- 组胺2受体拮抗剂使用者儿童哮喘风险升高(RR=1.57,95%CI 1.46-1.69)。
核心结论
- 孕期母亲使用抑酸药与儿童期哮喘风险升高相关,提示临床与家长在孕期决定是否使用抑酸药时需谨慎权衡子代哮喘风险。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Medline、Embase、Cochrane系统综述数据库、EBSCO、Web of Science和Google Scholar,检索时间从建库至2017年6月。
- 从556篇筛选文献中纳入8项基于人群的观察性研究,评估孕期抑酸药使用与儿童哮喘风险的关联。
主要发现
- 汇总所有研究,孕期抑酸药使用与儿童期哮喘风险升高相关(RR=1.45;95%CI 1.35-1.56;I2=0%;P<.00001)。
- 质子泵抑制剂使用者儿童期哮喘总体风险升高(RR=1.34;95%CI 1.18-1.52;I2=46%;P<.00001)。
- 组胺2受体拮抗剂使用者儿童期哮喘总体风险升高(RR=1.57;95%CI 1.46-1.69;I2=0%;P<.00001)。
关键数值与推荐
- 孕期抑酸药暴露与儿童哮喘关联的汇总RR=1.45(95%CI 1.35-1.56;I2=0%;P<.00001)。
- 质子泵抑制剂暴露的儿童哮喘RR=1.34(95%CI 1.18-1.52;I2=46%;P<.00001)。
- 组胺2受体拮抗剂暴露的儿童哮喘RR=1.57(95%CI 1.46-1.69;I2=0%;P<.00001)。
临床怎么用
- 对孕期考虑使用抑酸药的孕妇,应告知其子代儿童期哮喘风险可能升高,并结合母体适应证权衡利弊。
- 该证据来自观察性研究的荟萃分析,不能确立因果关系,临床决策需个体化。
局限性
- 纳入研究均未调整这些关联中所有已知的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The association between acid-suppressive drug exposure during pregnancy and childhood asthma has not been well established. OBJECTIVE: To conduct a systematic review and meta-analysis on this association to provide further justification for the current studies. DATA SOURCES: We searched PubMed, Medline, Embase, the Cochrane Database of Systematic Reviews, EBSCO Information Services, Web of Science, and Google Scholar from inception until June 2017. STUDY SELECTION: Observational studies in which researchers assessed acid-suppressive drug use during pregnancy and the risk of childhood asthma were included. DATA EXTRACTION: Of 556 screened articles, 8 population-based studies were included in the final analyses. RESULTS: When all the studies were pooled, acid-suppressive drug use in pregnancy was associated with an increased risk of asthma in childhood (relative risk [RR] = 1.45; 95% confidence interval [CI] 1.35-1.56; I2 = 0%; P < .00001). The overall risk of asthma in childhood increased among proton pump inhibitor users (RR = 1.34; 95% CI 1.18-1.52; I2 = 46%; P < .00001) and histamine-2 receptor antagonist users (RR = 1.57; 95% CI 1.46-1.69; I2 = 0%; P < .00001). LIMITATIONS: None of the researchers in the studies in this meta-analysis adjusted for the full panel of known confounders in these associations. CONCLUSIONS: The evidence suggests that prenatal, maternal, acid-suppressive drug use is associated with an increased risk of childhood asthma. This information may help clinicians and parents to use caution when deciding whether to take acid-suppressing drugs during pregnancy because of the risk of asthma in offspring.
引用
- Lai T, Wu M, Liu J, et al. Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis. Pediatrics. 2018. PMID: 29326337. doi:10.1542/peds.2017-0889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。